摘要
目的探讨沙美特罗/氟替卡松与噻托溴铵联合治疗D组稳定期慢性阻塞性肺疾病(COPD)患者的效果。方法将90例D组稳定期COPD患者分为三组:A组(沙美特罗/氟替卡松+噻托溴铵)、B组(沙美特罗/氟替卡松)和C组(噻托溴铵),每组各30例。对三组患者治疗前和治疗3个月后的呼吸困难评分、肺功能指标进行比较。结果治疗3个月后,A组患者呼吸困难评分及肺功能改善均优于B、C两组,差异有统计学意义(P<0.05)。结论联合使用沙美特罗/氟替卡松和噻托溴铵比单用沙美特罗/氟替卡松或单用噻托溴铵可以更好地改善D组稳定期COPD患者的呼吸困难评分和肺功能。
Objective To explore the therapy efficacy of salmeterol/fluticasone combined tiotropium in treatment of group D stable COPD patients. Methods 90 cases of group D stable COPD patients were randomly divided into three groups, group A（salmeterol/fluticasone combined tiotropium）, group B（salmeterol/fluticasone） and group C（tiotropium）, 30 patients in each group. The dyspnea score and lung function were measured before and 3 months after the treatment respectively. Results Compared with the other groups, the dyspnea score and lung function were significantly improved in group A after 3 months treatment,the difference was statistically significant （P〈0.05）. Conclusion Combination treatment with salmeterol/fluticasone and tiotropium results in greater therapeutic benefits than salmeterol/fluticasone or tiotropium alone in group D stable COPD patients.
出处
《中国现代医生》
2016年第18期38-40,共3页
China Modern Doctor
基金
广东省东莞市科技计划项目(B200935)
